Development and Application of AI-Based Therapeutic Strategies for Esophageal Cancer Integrating Multimodal Imaging and Digital Pathology

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07203690

Enrollment

7000

Registered

2025-10-02

Start date

2025-12-01

Completion date

2027-12-01

Last updated

2025-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Cancer, Neoadjuvant Therapy

Brief summary

The purpose of this clinical study is to conduct a multi-center, big data study to create a neural network decision model for predicting treatment efficacy and prognosis based on multi-modal, multi-temporal imaging features combined with tumor microenvironment scores. It will also use various model interpretation techniques to clarify the role and mechanism of key biomarkers or strongly associated biomarker groups in treatment efficacy and prognosis. Ultimately, it aims to achieve the research and application of AI treatment strategies combining multi-modal imaging and digital pathology to guide clinicians in the personalized treatment strategies for patients with esophageal squamous cell carcinoma.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Aged 18-70 years; 2. Histologically confirmed esophageal carcinoma by biopsy; 3. No prior antitumor therapy received.

Exclusion criteria

1. Contraindications to MRI examination; 2. Poor compliance with antitumor therapy; 3. Unwillingness to participate in the study; 4. Image quality inadequate for diagnostic requirements.

Design outcomes

Primary

Measure	Time frame	Description
Pathological Complete Response (pCR) Rate	January 2025 - December 2027	The proportion of patients achieving pathological complete response (ypT0 ypN0) after neoadjuvant therapy.
Overall Survival (OS)	January 2025 - December 2027	The time from treatment initiation to death from any cause.
Event-Free Survival (EFS)	January 2025 - December 2027	The time from treatment initiation to disease progression, recurrence, new primary cancer, or death.
Disease-Free Survival (DFS)	January 2025 - December 2027	The time from curative-intent surgery to disease recurrence or death.

Contacts

Primary ContactJinrong Qu

qjryq@126.com(86) 0371-65587595

Outcome results